Results 1 to 10 of about 9,323 (145)

Immune-Checkpoint-Inhibitor-Related Bullous Pemphigoid During Avelumab Maintenance Therapy in a Patient With Metastatic Renal Pelvic Carcinoma: A Case Report. [PDF]

IJU Case Rep
ABSTRACT Introduction Bullous pemphigoid is a rare cutaneous, immune‐related adverse event, and avelumab‐associated cases are extremely rare. Case Presentation A 76‐year‐old man receiving avelumab maintenance therapy for recurrent renal pelvic carcinoma developed pruritic erythema and tense blisters 20 days after the first dose.
Nara T, Furihata K, Kikuchi A, Sekine Y, Sato H, Kobayashi M, Yamamoto R, Saito M, Narita S, Habuchi T.   +9 more
europepmc   +2 more sources

Bullous Pemphigoid Disease Area Index Pruritus, Activity, and Damage During Biologic Therapy in Bullous Pemphigoid: An International Dual-Center Study. [PDF]

J Dermatol
ABSTRACT Biologic therapies targeting Type 2 inflammation are increasingly used in bullous pemphigoid, yet the relationship between pruritus and distinct disease domains remains incompletely defined. We conducted a retrospective international dual‐center study of 25 patients with bullous pemphigoid treated with dupilumab, omalizumab, or tralokinumab ...
Cascio Ingurgio R, Alfano A, Syed A, Gargiulo L, Narcisi A, Costanzo A, Murrell DF.   +6 more
europepmc   +2 more sources

Tocilizumab for severe and refractory mucous membrane pemphigoid. [PDF]

J Eur Acad Dermatol Venereol
Elevated IL‐6 levels identified in mucous membrane pemphigoid support IL‐6 blockade, with tocilizumab demonstrating clinical benefit in nine patients with severe and refractory mucous membrane pemphigoid. Abstract Background Mucous membrane pemphigoid (MMP) is a rare autoimmune blistering disease involving mucous membranes with a potentially ...
Tedbirt B, Maho-Vaillant M, Gueudry J, Golinski ML, Marcaillou M, Bergeret B, Chambon G, Bouchetemble P, Bekri S, Tebani A, Maillard H, Morice C, Vautier A, Libert EP, Le Roux-Villet C, Carrette M, Boyer O, Hébert V, Calbo S, Gillibert A, Joly P.   +20 more
europepmc   +2 more sources

Dyshidrosiform Bullous Pemphigoid

Medicina, 2021
Dyshidrosiform bullous pemphigoid is a variant of bullous pemphigoid. At least 84 patients with dyshidrosiform bullous pemphigoid have been described. Dyshidrosiform bullous pemphigoid usually presents with pruritic blisters in elderly individuals; the ...
Philip R. Cohen
doaj   +1 more source

Prevalence, Spectrum and Clinical Implications of Malignancies in Patients with Bullous Pemphigoid

Acta Dermato-Venereologica, 2023
Current research on the malignancy rate and spectrum of malignancies in patients with bullous pemphigoid is contradictory. The aims of this study were to determine the prevalence and spectrum of malignancy in patients with bullous pemphigoid and to ...
Sharon Baum, Shani Steinberg, Ido Tzanani , Aviv Barzilai , Anna Lyakhovitsky   +4 more
doaj   +1 more source

Immunomodulator Galectin-9 is Increased in Blood and Skin of Patients with Bullous Pemphigoid

Acta Dermato-Venereologica, 2021
Massive recruitment of eosinophils into the dermis is a hallmark of bullous pemphigoid pathogenesis. Identifying the chemoattractant(s) guiding eosinophils into the skin in bullous pemphigoid is a prerequisite to thera­peutic targeting of eosinophil ...
Jasper Pruessmann, Wiebke Pruessmann, Maike M. Holtsche, Beke Linnemann, Christoph M. Hammers, Nina van Beek, Detlef Zillikens, Enno Schmidt, Christian D. Sadik   +8 more
doaj   +1 more source

Dipeptidyl-Peptidase 4 Inhibitor-Induced Variants of Bullous Pemphigoid: A Case Series of Four Patients

Case Reports in Dermatology, 2022
Bullous pemphigoid is the most common acquired bullous disease with an autoimmune basis and a tendency to involve mostly old people. By rising incidence of diabetes all over the world, consumption of antidiabetes medications has also increased.
Kamran Balighi, Sama Heidari, Mohammadreza Kavyani, Kambiz Kamyab Hesari, Nasim Tootoonchi   +4 more
doaj   +1 more source

Comorbidity in bullous pemphigoid: up-date and clinical implications

Frontiers in Immunology, 2023
Bullous pemphigoid is the most common autoimmune blistering disease in industrialized countries and particularly affects the elderly. In this patient population, comorbid diseases are frequent and may complicate management and treatment of bullous ...
Johanna Huttelmaier, Sandrine Benoit, Matthias Goebeler   +2 more
doaj   +1 more source

The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study

BMC Endocrine Disorders, 2021
Background Bullous pemphigoid is the most common bullous chronic autoimmune skin disease. Recent studies have suggested dipeptidyl-peptidase 4 inhibitors as possible predisposing agents of bullous pemphigoid.
Vaia Lambadiari, Aikaterini Kountouri, Foteini Kousathana, Emmanouil Korakas, Georgios Kokkalis, Sofia Theotokoglou, Lina Palaiodimou, Pelagia Katsimbri, Ignatios Ikonomidis, Konstantinos Theodoropoulos, Evangelia Papadavid   +10 more
doaj   +1 more source

Risk of Serious Infections in Patients with Bullous Pemphigoid: A Population-based Cohort Study

Acta Dermato-Venereologica, 2023
Patients with bullous pemphigoid are susceptible to serious infections, which are the leading cause of death in these patients. The aims of this population-based cohort study were to investigate the incidence and spectrum of serious infections in ...
Tsung-Hsien Chang, Chun-Ying Wu, Yun-Ting Chang, Ying-Syuan Lyu, Chen-Yi Wu   +4 more
doaj   +1 more source